ArticleGland surgery2024
Risk factors for cervical lymph node metastasis at different lateral levels in papillary thyroid cancer: level III as the central hub.
Article in Gland surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recursive partitioning analysis improves risk stratification in node-negative differentiated thyroid cancer: a retrospective cohort study.Gland surgery · 2026Article
- Feasibility and outcomes of remote-access endoscopic and robotic lateral neck dissection for thyroid cancer: a scoping review.Gland surgery · 2025Review
- Is it possible to rule out level II and level VB dissection in patients with metastatic papillary thyroid cancer?Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As the most prevalent histological type of thyroid cancer, the prognosis of papillary thyroid cancer (PTC) is closely related to cervical lymph node metastasis (LNM), particularly in the case of lateral LNM (LLNM). The patterns of cervical LNM in PTC remain inconclusive. We aim to assess the risk factors for LLNM and extranodal extension (ENE) at different lateral levels in N1b PTC patients. Methods: A total of 486 PTC patients with pathologically diagnosed N1b, who underwent thyroidectomy with central and lateral neck lymph node dissection at our hospital between January 2019 and December 2021, were retrospectively retrieved. The metastatic status of different lateral levels was recorded. Further correlation analysis was conducted. Results: Based on the correlation analysis, binary logistic regression analysis indicated that upper location [odds ratio (OR) =3.067; P<0.001; 95% confidence interval (CI): 2.075-4.534] and central LNM-ENE (CLNM-ENE) (OR =2.036; P=0.04; 95% CI: 1.044-3.970) are predictive factors for level II metastasis. Additionally, upper location (OR =2.106; P<0.001; 95% CI: 1.404-3.159) and CLNM (OR =2.664; P<0.001; 95% CI: 1.681-4.222) were found to be predictive factors for level III metastasis. LLNM at level IV was closely associated only with CLNM. Level III-ENE (OR =2.347; P=0.03; 95% CI: 1.065-5.176) was found to be highly correlated with level V metastasis. As for ENE, level III-ENE was found to be a risk factor for ENE in all other levels (II, IV, V), while ENE in the other lateral cervical regions also increased the risk for level III. Conclusions: Despite some uncertainties, LLNM remains closely associated with the upper location of PTC. Meanwhile, level III functions as the hub of the lateral neck, with level III-ENE increasing the risk of LLNM in level V, and significantly raising the probability of ENE in other lateral cervical regions. LLNM have its inherent patterns, as evidenced in the study, but also have a degree of unpredictability, therefore an accurate preoperative assessment is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.